多西他赛联合替吉奥治疗晚期胃癌的临床疗效观察
马好霞;刘丽娜;李晋生;张芳;杨浩浩
【期刊名称】《肿瘤药学》 【年(卷),期】2014(000)004
【摘要】Objective To assess the efficacy and safety of docetaxel plus S-1 in the treatment of advanced gastric cancer. Methods From March 2010 to June 2011, 138 patients with advanced gastric cancer admitted in our hospital were selected and randomly divided into experimental group and control group. The control group was given front-line clinical treatment of DPF, while the experimental group was treated by docetaxel and S-1. The short-term efficacy and incidence of side-effects were ob-served and compared after treatment. Results The effective rate of the experimental group was significantly higher than that of the control group (58.6%vs. 41.2%, P<0.05). The main adverse reactions observed during treatment included hair loss, nausea, vom-iting, myelosuppression and liver function damage, while no adverse symptoms of heart or kidney was observed. The incidence of adverse reactions in experimental group was significantly lower than that in the control group (P<0.05). Conclusion Docetaxel plus S-1 was more effective and safer than the current front-line clinical DPF treatment in the treatment of advanced gastric cancer.%目的：探讨多西他赛联合替吉奥治疗晚期胃癌的临床效果和安全性。方法选择2010年3月～2011年6月
多西他赛联合替吉奥治疗晚期胃癌的临床疗效观察
